Provided by Tiger Trade Technology Pte. Ltd.

LUYE PHARMA

1.940
-0.190-8.92%
Volume:104.66M
Turnover:202.39M
Market Cap:7.75B
PE:10.47
High:2.125
Open:2.125
Low:1.875
Close:2.130
52wk High:3.940
52wk Low:1.730
Shares:4.00B
HK Float Shares:4.00B
Volume Ratio:2.98
T/O Rate:2.62%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.185
ROE:4.14%
ROA:2.44%
PB:0.41
PE(LYR):10.47
PS:1.05

Loading ...

Luye Pharma Completes Early Redemption of US$180.00 Million 6.25% Convertible Bonds

Bulletin Express
·
Jul 06

Movement Alert|Luye Pharma Rises 5.91% in Regular Trading, UBS Increases Stake Amid Innovative Drug Sector Rebound

Market Focus
·
Jul 03

Movement Alert|Luye Pharma Falls 6.91% in Regular Trading, Innovative Drug Sector Under Sustained Pressure

Market Focus
·
Jun 30

Luye Pharma: Shareholders Pass All AGM Resolutions with Overwhelming Majority, Re-Elect Directors and Renew Key Mandates

Bulletin Express
·
Jun 26

Luye Pharma Shareholders Back Share Issuance Mandate at AGM Poll

Reuters
·
Jun 26

Shandong Boan Biotech shareholders adopt restricted share unit incentive scheme at AGM

Reuters
·
Jun 22

Luye Pharma Group Drug Meets Main Goal of Phase 2 Study

MT Newswires Live
·
Jun 17

Daily Insight into Hong Kong Stocks: DeepSeek Secures $50 Billion Funding, Yum China Acquires Full Ownership of Pizza Hut in Mainland China

Stock News
·
Jun 17

LUYE PHARMA's Novel Drug LY03015 Shows Positive Phase II Results in China for Tardive Dyskinesia

Stock News
·
Jun 16

Luye Pharma reports strong Phase 2 data for first-in-class TD therapy LY03015, sets stage for global Phase 3

Bulletin Express
·
Jun 16

Luye Pharma says LY03015 meets primary endpoint in China Phase 2 tardive dyskinesia trial

Reuters
·
Jun 16

TransThera Sciences names Sun Delong chief operating officer

Reuters
·
Jun 12

Luye Pharma Group's Bond Buyback Undersubscribed

MT Newswires Live
·
Jun 12

Shandong Boan Biotech licenses U.S. rights to dulaglutide biosimilar BA5101 to partner

Reuters
·
Jun 11

Luye Pharma Completes $180 Million Convertible Bond Sale

MT Newswires Live
·
Jun 11

LUYE PHARMA Successfully Issues $180 Million Convertible Notes Due 2031

Stock News
·
Jun 11

Luye Pharma finalises US$180 million 5.25% convertible bond issue maturing 2031

Bulletin Express
·
Jun 11

Hong Kong Stocks Extend Losses Amid Middle East Flare-Up; Luye Pharma Proposes Debt Offering

MT Newswires Live
·
Jun 04

Hong Kong Market Midday Update: Hang Seng Index Down 1.4% as Semiconductor Sector Defies Broader Decline

Stock News
·
Jun 04

Luye Pharma Plans $180 Million Convertible Bond Sale, Bond Buyback

MT Newswires Live
·
Jun 04